DXB 2.63% 55.5¢ dimerix limited

DXB Chart, page-118

  1. 6,434 Posts.
    lightbulb Created with Sketch. 5274
    Something to note: oral treatment & if successful:

    https://www.google.com.au/amp/s/www.nytimes.com/2021/10/17/health/covid-treatment-access-molnupiravir.amp.html

    3% vaccination rate across Africa, quoted in this article. That’s appalling. Oral treatments for COVID-19 should know no boundaries. They don’t need cold-chain nor expense or expertise to hospitals administering IV expensive MABS. Other Drug companies (ie Merck) will allow out-licensing with cheaper cost to Govts/patients for oral antivirals +/- WHO support.

    https://www.reuters.com/business/healthcare-pharmaceuticals/aurobindo-pharma-stop-molnupiravir-trial-moderate-covid-19-patients-2021-10-08/

    Interesting article above on Molnupiravir trials in India.

    GLTAH
 
watchlist Created with Sketch. Add DXB (ASX) to my watchlist
(20min delay)
Last
55.5¢
Change
-0.015(2.63%)
Mkt cap ! $305.1M
Open High Low Value Volume
56.0¢ 58.5¢ 54.0¢ $3.231M 5.779M

Buyers (Bids)

No. Vol. Price($)
1 1118 55.5¢
 

Sellers (Offers)

Price($) Vol. No.
56.5¢ 239062 1
View Market Depth
Last trade - 16.10pm 19/06/2024 (20 minute delay) ?
DXB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.